Literature DB >> 1402636

Use of smokeless tobacco: blood pressure elevation and other health hazards found in a large-scale population survey.

G M Bolinder1, B O Ahlborg, J H Lindell.   

Abstract

Health hazards associated with the use of smokeless tobacco were evaluated in a cross-sectional study of 97,586 Swedish construction workers undergoing health examinations in 1971-74. All users of smokeless tobacco only (5014 subjects) and all exclusive smokers of > or = 15 cigarettes daily (8823 subjects) were compared with all non-users of any tobacco (23,885). Both smokeless tobacco users and smokers showed higher prevalences of circulatory and respiratory disorders. Hypertension was most common in smokeless tobacco users. In the 45- to 56-years age group, the odds ratio for a diastolic blood pressure of > 90 mmHg was 1.8 (95% CI, 1.5-2.1), and for a systolic blood pressure > 160 mmHg, 1.7 (95% CI, 1.3-2.1). Smokers showed the lowest prevalence of hypertension. Disability pensions due to cardiovascular disease were nearly 50% more frequent in both smokeless tobacco users and smokers. These findings indicate that an increased cardiovascular risk is also associated with the use of smokeless tobacco.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1402636     DOI: 10.1111/j.1365-2796.1992.tb00593.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  22 in total

1.  Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers.

Authors:  G Bolinder; L Alfredsson; A Englund; U de Faire
Journal:  Am J Public Health       Date:  1994-03       Impact factor: 9.308

2.  Utility of Responsiveness Theory for Classifying Supportive Behaviors to Enhance Smokeless Tobacco Cessation.

Authors:  Laura Akers; Judith S Gordon; Zoe Brady; Judy A Andrews; Herbert H Severson
Journal:  Nicotine Tob Res       Date:  2015-12-30       Impact factor: 4.244

3.  Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data.

Authors:  Ruchika Gupta; Sanjay Gupta; Shashi Sharma; Dhirendra N Sinha; Ravi Mehrotra
Journal:  Nicotine Tob Res       Date:  2019-01-01       Impact factor: 4.244

4.  Use of tobacco products and gastrointestinal morbidity: an endoscopic population-based study (the Kalixanda study).

Authors:  Pertti Aro; Jukka Ronkainen; Tom Storskrubb; Michael Vieth; Lars Engstrand; Sven-Erik Johansson; Elisabeth Bolling-Sternevald; Gunilla Bolinder; Kjell Alving; Nicholas J Talley; Lars Agréus
Journal:  Eur J Epidemiol       Date:  2010-07-29       Impact factor: 8.082

Review 5.  Effect of smokeless tobacco (snus) on smoking and public health in Sweden.

Authors:  J Foulds; L Ramstrom; M Burke; K Fagerström
Journal:  Tob Control       Date:  2003-12       Impact factor: 7.552

6.  Nicotine delivery capabilities of smokeless tobacco products and implications for control of tobacco dependence in South Africa.

Authors:  O A Ayo-Yusuf; T J P Swart; W B Pickworth
Journal:  Tob Control       Date:  2004-06       Impact factor: 7.552

7.  Socio-demographic, lifestyle and health characteristics among snus users and dual tobacco users in Stockholm County, Sweden.

Authors:  Karin Engström; Cecilia Magnusson; Maria Rosaria Galanti
Journal:  BMC Public Health       Date:  2010-10-18       Impact factor: 3.295

8.  Current use of smokeless tobacco among adolescents in the Republic of Congo.

Authors:  Emmanuel Rudatsikira; Adamson S Muula; Seter Siziya
Journal:  BMC Public Health       Date:  2010-01-14       Impact factor: 3.295

9.  Association of exclusive smokeless tobacco consumption with hypertension in an adult male rural population of India.

Authors:  Ambarish Pandey; Nivedita Patni; Sasmit Sarangi; Mansher Singh; Kartavya Sharma; Ananth K Vellimana; Somdutta Patra
Journal:  Tob Induc Dis       Date:  2009-11-24       Impact factor: 2.600

10.  Effects of smokeless tobacco "Maras powder" use on nitric oxide and cardiovascular risk parameters.

Authors:  Aytekin Guven; Fatma Tolun
Journal:  Int J Med Sci       Date:  2012-10-25       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.